AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Parthenon Therapeutics.

    Client Virtual Booth

    PARTHENON THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Parthenon Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    40 Guest St. Boston, MA 02135
    Telephone
    Telephone
    617.870.3363
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://parthenontx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/parthenontherapeutics
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    XtalPi and Parthenon Enter into AI-Powered Antibody Discovery Partnership

    Details:

    Under this agreement, XtalPi will grant Parthenon Therapeutics access to its proprietary XupremAb™ antibody discovery platform, which is a collection of solutions that leverage AI and wet lab techniques to deliver therapeutic antibody candidates.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Recipient: XtalPi

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration September 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded ...

    Details:

    PRTH-101 is a novel discoidin domain receptor 1 (DDR1) antagonist monoclonal antibody that is expressed at very high levels in solid tumors with low levels of T cell infiltration, it is being investiated for the treatment of immune-excluded solid tumors.


    Lead Product(s): IgG1 Monoclonal Antibody,Pembrolizumab

    Therapeutic Area: Oncology Product Name: PRTH-101

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    transo-pharm-handels-gmbh-m-2024-05-20

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search